MedTrace Logo

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

NCT04155541 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-05-23

No results posted yet for this study

Summary

Secondary data collection study: safety and efficacy of VIZIMPRO under Japanese medical practice

Conditions

  • EGFR Mutation-positive Inoperable or Reccrent NSCLC

Interventions

DRUG

dacomitinib hydrate

The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose should be reduced appropriately according to the patient's condition.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-24
Primary Completion
2025-04-25
Completion
2025-04-25

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04155541 on ClinicalTrials.gov